Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash equival ...
CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...
Continuing Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA) Following Positive Phase 2b RSVHR Results for Zelicapavir, an N-Protein Inhibitor in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback